Record · corpus.blog/posts/01a0f576-b8a6-73e7-83a6-a3eb6c42b338
A phase 1/2 study of vusolimogene oderparepvec (RP1) in primary melanoma (mel) to reduce the risk of sentinel lymph node (SLN) metastasis.
$whoami : echo “tp53(ashish), ml + {medicine, biology} tinkerer” - tp53(ashish)’s home on the interwebs · published 30 September 2026
A record is what was published and who pointed at it. The text of the post is not held here: read it at the source, or at its Wayback capture.
0blogs citing
- First cited
- —
- Most recent
- —
- Rank this month
- not ranked
- External links
- 0
- Words captured
- 460
Cited by
No blog we hold has cited this post yet.
Similar posts
Can Viruses Fight Cancer? What Tudriqev Means for Patients With Melanoma
cancerresearch.org
24 Aug 2026
Quantifying immunosuppressive barriers using a mathematical framework of tumor-associated myeloid cell mediated resistance in oncolytic virotherapy
people.maths.ox.ac.uk
4 Oct 2026
Dene’s story: helping the future of cancer treatment
guysandstthomas.nhs.uk
1 Oct 2026
Links from this post
This post doesn't link to any pages we've captured.